Diaceutics
EU IVDR Implementation Woes Could Severely Limit Cancer Companion Test, Precision Therapy Access
Premium
The EC has stuck with its timeline to implement the new regulations in eight months, raising concerns for cancer patients' ability to receive biomarker testing and treatments.
LGC SeraCare Joins Diaceutics DXRX Network for Precision Medicine Diagnostics
The partnership will introduce additional types of test reference materials to users of the platform, including the Seraseq FFPE Tumor Fusion RNA Reference Material v4.
The companies will work with labs to improve payors' understanding of the costs of performing PD-L1 testing and the value it provides to patient care.
The DXRX marketplace, planned for launch in the fourth quarter of 2020, will provide a way for pharmaceutical companies, diagnostic firms, and laboratories to collaborate.
Amid COVID-19, Lower Cancer Diagnosis Rates Mean Fewer Patients Getting Molecular Tests, Treatment
Premium
Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.